Article
作者: Matsuda, Yutaka ; Iwabuchi, Ryutaro ; Hironiwa, Naoka ; Shiraiwa, Hirotake ; Kashima, Kenji ; Muraoka, Masaru ; Kawa, Tatsuya ; Shimizu, Yuichiro ; Yeo, Chiew Ying ; Sakamoto, Akihisa ; Kuroi, Haruka ; Kamikawaji, Shogo ; Shinozuka, Junko ; Asanuma, Kentaro ; Yamazaki, Masaki ; Mimoto, Futa ; Kitazawa, Takehisa ; Ishikawa, Shumpei ; Ishii, Shinya ; Ho, Samantha Shu Wen ; Tsunenari, Toshiaki ; Kamata-Sakurai, Mika ; Takahashi, Noriyuki ; Chichili, Priyanka ; Azuma, Yumiko ; Kayukawa, Yoko ; Shimizu, Shun ; Aburatani, Hiroyuki ; Kinoshita, Yasuko ; Naoi, Sotaro ; Gan, Siok Wan ; Igawa, Tomoyuki ; Mikami, Hirofumi ; Nagano, Hiroaki ; Feng, Shu ; Pang, Chai Ling
AbstractSmall-cell lung cancer (SCLC) is an aggressive cancer for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives for ICI-resistant tumors, but not all patients with SCLC are responsive. Herein, to integrate CD137 costimulatory function into a T-cell engager format and thereby augment therapeutic efficacy, we generated a CD3/CD137 dual-specific Fab and engineered a DLL3-targeted trispecific antibody (DLL3 trispecific). The CD3/CD137 dual-specific Fab was generated to competitively bind to CD3 and CD137 to prevent DLL3-independent cross-linking of CD3 and CD137, which could lead to systemic T-cell activation. We demonstrated that DLL3 trispecific induced better tumor growth control and a marked increase in the number of intratumoral T cells compared with a conventional DLL3-targeted bispecific T-cell engager. These findings suggest that DLL3 trispecific can exert potent efficacy by inducing concurrent CD137 costimulation and provide a promising therapeutic option for SCLC.